Surgical outcomes and prognostic factors for patients with gastric cancer spinal metastasis.
gastric cancer
spine metastasis
surgery
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2019
2019
Historique:
received:
14
01
2019
accepted:
03
07
2019
entrez:
16
8
2019
pubmed:
16
8
2019
medline:
16
8
2019
Statut:
epublish
Résumé
To investigate the outcome and prognostic factors of surgery in treating gastric cancer spinal metastasis (GCSM). A total of 17 patients with GCSM who have undertaken spinal surgeries have been identified. Kaplan-Meier method and univariate analysis are adopted to investigate the prognostic factors affecting overall survival (OS) and progression-free survival (PFS). The median PFS and OS are 11.3 months (95% CI: 7.8-14.9 months) and 11.9 months (95% CI: 8.4-15.4 months), respectively. Postoperatively, all patients had substantial pain relief, with mean visual analog scale score descending from 6.6±1.6 to 3.4±1.2. Meanwhile, patients also showed improved neurological functions, with 8 of them having improvements of at least one level in Frankel classification. Univariate analysis presented that patients with carcinoembryonic antigen (CEA)<6 µg/L ( Surgery is an efficient option in treating GCSM, due to its efficacy in pain alleviation, function restoration, and stability reconstruction. Low levels of CEA, LDH, ALP, and high Tokuhashi score (>6) are all favorable factors for better OS, whereas low levels of LDH, ALP, and application of bone cement are related with longer PFS.
Identifiants
pubmed: 31413637
doi: 10.2147/CMAR.S201372
pii: 201372
pmc: PMC6662173
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6971-6979Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Clin Gastroenterol. 2001 Jan;32(1):41-4
pubmed: 11154168
Dis Markers. 2000;16(3-4):105-10
pubmed: 11381189
Neuro Oncol. 2005 Jan;7(1):64-76
pubmed: 15701283
Lancet. 2005 Aug 20-26;366(9486):643-8
pubmed: 16112300
Spine (Phila Pa 1976). 2005 Oct 1;30(19):2186-91
pubmed: 16205345
Ann Oncol. 2007 May;18(5):886-91
pubmed: 17298958
Eur Spine J. 2010 Feb;19(2):215-22
pubmed: 20039084
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):524-30
pubmed: 20452136
J Neurosurg Spine. 2011 Feb;14(2):172-6
pubmed: 21184643
Oncology. 2011;80(1-2):142-50
pubmed: 21677462
J Gastric Cancer. 2011 Mar;11(1):38-45
pubmed: 22076200
J Spinal Disord Tech. 2012 Feb;25(1):1-9
pubmed: 22143043
Chin J Cancer. 2012 Apr;31(4):197-206
pubmed: 22237040
World J Surg Oncol. 2012 Feb 15;10:37
pubmed: 22333159
Spine J. 2012 Dec;12(12):1083-92
pubmed: 23168136
Oncologist. 2013 Jun;18(6):744-51
pubmed: 23709750
PLoS One. 2013 Oct 28;8(10):e74402
pubmed: 24204569
Acta Pharmacol Sin. 2013 Dec;34(12):1535-44
pubmed: 24241351
PLoS One. 2014 Mar 07;9(3):e91068
pubmed: 24608789
J Neuroradiol. 2015 Jul;42(4):222-8
pubmed: 24998599
J Gastric Cancer. 2014 Sep;14(3):164-72
pubmed: 25328761
Tokai J Exp Clin Med. 2014 Dec 20;39(4):193-8
pubmed: 25504207
Gan No Rinsho. 1989 Sep;35(10):1149-52
pubmed: 2550686
J Korean Neurosurg Soc. 2014 Nov;56(5):431-5
pubmed: 25535523
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
PLoS One. 2015 Apr 16;10(4):e0124151
pubmed: 25879931
Tumour Biol. 2016 Aug;37(8):10981-92
pubmed: 26891667
World J Surg Oncol. 2017 Jan 6;15(1):8
pubmed: 28061855
Eur Spine J. 2018 Apr;27(4):859-867
pubmed: 28653097
Ann Surg Oncol. 2017 Nov;24(12):3683-3691
pubmed: 28895113
World J Gastroenterol. 2018 Jan 7;24(1):150-156
pubmed: 29358891
Acta Neurochir (Wien). 2018 Jul;160(7):1373-1376
pubmed: 29808457
Cancer Med. 2018 Aug;7(8):3662-3672
pubmed: 29984918
Jpn J Surg. 1983 May;13(3):173-6
pubmed: 6632389
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
J Am Coll Surg. 1998 Jul;187(1):64-8
pubmed: 9660027
J Cancer Res Clin Oncol. 1998;124(8):450-5
pubmed: 9750022